I found that I was losing the plot about what was where! Here’s my quick guide to priority pathogens and pipeline reviews. Corrections and amends gratefully received.

Priority Pathogen / Threat Lists

• CDC 2019: Newsletter is here, report itself is here.
• WHO 2017: Newsletter is here, report itself is here.
• CDC 2013: Report itself is here.
• ESKAPE list 2008-9: The original papers are here:
  • (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
  • (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12
• Comparative summary of all 4 priority pathogen lists as a PowerPoint deck is here.
  • Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class. 

Pipeline Reviews

• Reviews by WHO
  • WHO 2019: My newsletter is here, commentary by WHO staff is here, the pre-clinical pipeline review is here and is supported by a data-mining interface here; the clinical pipeline review is here.
  • WHO 2017: Newsletter is here, report is here, and manuscript about the review is here.
• Reviews by the Pew Trusts (all updated as of April 2020)
  • Go here for traditional therapeutics.
  • Go here for a visualization of pipeline changes during 2014-2019.
  • Non-traditional products are separately summarized here.
• Independent reviews
  • Clinical pipeline: Theuretzbacher et al. Nat Rev Microbiol 2020 (https://doi.org/10.1038/s41579-020-0340-0) is an extended commentary on the current pipeline by the group who did the WHO 2019 review. 
  • Clinical pipeline: Butler and Paterson, J Antibiot 2020 https://doi.org/10.1038/s41429-020-0291-8: Not open access, but you can view it online here.
  • Commercial view of recently approved drugs: Alan Carr 2020: Newsletter is here. Alan’s regularly updated summary analyzes products approved in the US since 2009.
  • Non-traditional products: Theuretzbacher and Piddock, Cell Host Microb 2019 (https://doi.org/10.1016/j.chom.2019.06.004) and Rex et al. Nat Commun 2019,  https://doi.org/10.1038/s41467-019-11303-9: Focused reviews and discussions of non-traditional products. Go here for a newsletter about these two papers.
  • Preclinical pipeline: Theuretzbacher et al. Nat Rev Microbiol 2019 (https://www.nature.com/articles/s41579-019-0288-0) surveys 400+ active preclinical programs.